Core Insights - WuXi AppTec's stock price increased by 2.02% on November 12, reaching 94.37 CNY per share, with a market capitalization of 281.57 billion CNY [1] - The company has seen a year-to-date stock price increase of 76.86%, with a recent 5-day increase of 0.06% and a 20-day decrease of 5.12% [1] Financial Performance - For the period from January to September 2025, WuXi AppTec reported a revenue of 32.857 billion CNY, representing a year-on-year growth of 18.61%, and a net profit attributable to shareholders of 12.076 billion CNY, which is an increase of 84.84% [2] - The company has distributed a total of 14.06 billion CNY in dividends since its A-share listing, with 10.406 billion CNY distributed over the last three years [3] Shareholder Information - As of September 30, 2025, WuXi AppTec had 274,100 shareholders, an increase of 16.39% from the previous period [2] - The largest shareholders include Hong Kong Central Clearing Limited, which holds 249 million shares, a decrease of 52.607 million shares from the previous period [3]

Core Viewpoint - Nanjing Pharmaceutical's stock price has shown significant volatility, with a year-to-date increase of 51.38% but a recent decline in the last 60 days by 27.90% [2][3] Company Overview - Nanjing Pharmaceutical, established on December 27, 2006, and listed on March 26, 2020, focuses on the research, production, and sales of antiviral and infectious disease treatment drugs, as well as medications for major diseases like cardiovascular diseases and diabetes [2] - The company operates entirely in the chemical drug formulation sector, with 100% of its revenue derived from this area [2] Financial Performance - For the period from January to September 2025, Nanjing Pharmaceutical reported a revenue of 83.15 million yuan, a year-on-year decrease of 66.89%, and a net profit attributable to shareholders of -68.63 million yuan, reflecting a 19.96% decline [3] - The company has not distributed any dividends in the last three years, with a total payout of 40.74 million yuan since its A-share listing [4] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 49.13% to 14,100, while the average number of tradable shares per person decreased by 32.95% to 19,441 shares [3] - New institutional shareholders include several funds from GF Fund Management, indicating a shift in the shareholder base [4] Market Activity - Nanjing Pharmaceutical's stock experienced a net outflow of 529,500 yuan in major funds, with significant buying and selling activity observed [1] - The stock has appeared on the "Dragon and Tiger List" seven times this year, indicating notable trading activity [2]

Core Viewpoint - Huason Pharmaceutical's stock has shown a significant increase this year, with a year-to-date rise of 31.24%, indicating strong market interest and performance [2]. Group 1: Stock Performance - As of November 12, Huason Pharmaceutical's stock price rose by 2.05% to 16.95 CNY per share, with a market capitalization of 7.078 billion CNY [1]. - The stock has experienced a 3.99% increase over the last five trading days and a 1.13% increase over the last 20 days, while it has decreased by 5.65% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Huason Pharmaceutical reported a revenue of 626 million CNY, reflecting a year-on-year growth of 1.90%, while the net profit attributable to shareholders was 72.4556 million CNY, a decrease of 2.84% year-on-year [3]. - The company has distributed a total of 192 million CNY in dividends since its A-share listing, with 100 million CNY distributed in the last three years [4]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased to 33,100, with an average of 9,063 circulating shares per person, a slight decrease of 0.83% [3]. - The fifth largest circulating shareholder, Hong Kong Central Clearing Limited, reduced its holdings by 1.4123 million shares to 2.6207 million shares [4]. Group 4: Business Overview - Huason Pharmaceutical, established on November 4, 1996, operates in the pharmaceutical industry, focusing on research, production, and sales, with a revenue composition that includes 34.24% from ENT medications, 23.16% from digestive system medications, and 18.37% from psychiatric medications [2]. - The company is categorized under the pharmaceutical and biological industry, specifically in traditional Chinese medicine and generic drugs [2].

资金流入方面，港股创新药精选ETF最新资金流入流出持平。拉长时间看，近5个交易日内，合计"吸金"1070.71万元。 港股创新药精选ETF紧密跟踪恒生港股通创新药精选指数，恒生港股通创新药精选指数旨在反映可经港股通买卖，业务与创新药研究、开发及生产相关的香 港上市公司之表现。 数据显示，截至2025年10月8日，恒生港股通创新药精选指数前十大权重股分别为百济神州、中国生物制药、信达生物、石药集团、康方生物、三生制药、 翰森制药、科伦博泰生物-B、再鼎医药、诺诚健华，前十大权重股合计占比72.15%。 （文中个股仅作示例，不构成实际投资建议。基金有风险，投资需谨慎。） 截至2025年11月12日 09:51，恒生港股通创新药精选指数强势上涨3.17%，成分股百济神州上涨7.29%，映恩生物-B上涨4.74%，康方生物上涨4.63%，药捷安 康-B，三生制药等个股跟涨。港股创新药精选ETF(520690)上涨2.90%，最新价报0.92元。拉长时间看，截至2025年11月11日，港股创新药精选ETF近2周累计 上涨0.56%，涨幅排名可比基金1/2。 流动性方面，港股创新药精选ETF盘中换手8.57%，成交485 ...

Core Viewpoint - The stock of Shuyou Shen has shown significant volatility, with a year-to-date increase of 408.10%, but a recent decline over the past 60 days of 24.47% [1][2] Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and listed on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1] - The main revenue sources are: 59.17% from injectable mouse nerve growth factor (Sutai Sheng), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Financial Performance - For the period from January to September 2025, Shuyou Shen reported operating revenue of 181 million yuan, a year-on-year decrease of 30.82%. The net profit attributable to the parent company was -30.69 million yuan, a year-on-year decrease of 227.71% [2] - The company has distributed a total of 771 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 46,500, a rise of 46.97%. The average circulating shares per person decreased by 31.98% to 9,745 shares [2] - The top ten circulating shareholders include notable funds such as Xingquan Helun Mixed A and Yifangda Healthcare Industry Mixed A, with changes in their holdings noted [3] Market Activity - On November 12, the stock price rose by 2.00% to 37.65 yuan per share, with a trading volume of 530 million yuan and a turnover rate of 3.17%. The total market capitalization reached 17.988 billion yuan [1] - The stock has appeared on the daily trading list (龙虎榜) eight times this year, with the most recent occurrence on October 31, where it recorded a net purchase of 373 million yuan [1]

Core Viewpoint - The stock of Ailis has shown significant growth this year, with a notable increase in revenue and net profit, indicating strong business performance and investor interest [1][2]. Group 1: Stock Performance - As of November 12, Ailis's stock price increased by 2.02% to 102.57 CNY per share, with a total market capitalization of 46.156 billion CNY [1]. - Year-to-date, Ailis's stock price has risen by 73.55%, with a 1.56% increase over the last five trading days, a 3.47% decrease over the last 20 days, and a 15.16% increase over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Ailis reported a revenue of 3.733 billion CNY, representing a year-on-year growth of 47.35%, and a net profit attributable to shareholders of 1.616 billion CNY, up 52.01% year-on-year [2]. - Cumulatively, Ailis has distributed 653 million CNY in dividends since its A-share listing [3]. Group 3: Shareholder and Institutional Holdings - As of September 30, 2025, Ailis had 19,100 shareholders, an increase of 46.82% from the previous period, with an average of 23,551 circulating shares per shareholder, down 31.89% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 20.9471 million shares, an increase of 10.5693 million shares from the previous period [3].

Core Viewpoint - Zai Jian Pharmaceutical has shown a significant stock price increase of 59.32% year-to-date, despite recent fluctuations in trading performance [1][2] Company Overview - Zai Jian Pharmaceutical, established on March 18, 2009, and listed on January 23, 2020, is located in Kunshan, Jiangsu Province, and focuses on the research, production, and sales of chemical and biological new drugs [1][2] - The company's main revenue source is pharmaceuticals, accounting for 99.97% of total revenue, with minimal contributions from intermediates and asset leasing [1] Financial Performance - For the period from January to September 2025, Zai Jian Pharmaceutical reported a revenue of 593 million yuan, representing a year-on-year growth of 54.49% [2] - The company recorded a net profit attributable to shareholders of -93.42 million yuan, showing a year-on-year increase of 4.58% [2] Stock Market Activity - As of November 12, Zai Jian Pharmaceutical's stock price was 99.27 yuan per share, with a market capitalization of 26.278 billion yuan [1] - The stock has experienced a trading volume of 50.129 million yuan, with a turnover rate of 0.19% [1] - The stock has appeared on the "Dragon and Tiger List" once this year, with a net buy of 187 million yuan on October 31 [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 8,809, with an average of 30,049 circulating shares per person [2] - Notable institutional shareholders include China Europe Medical Health Mixed A and Industrial Bank Frontier Medical Stock A, with varying changes in their holdings [2]

11月12日，昭衍新药盘中上涨2.00%，截至09:46，报33.07元/股，成交9281.79万元，换手率0.45%，总 市值247.85亿元。 资金流向方面，主力资金净流入146.84万元，特大单买入118.01万元，占比1.27%，卖出118.88万元，占 比1.28%；大单买入1384.30万元，占比14.91%，卖出1236.59万元，占比13.32%。 昭衍新药今年以来股价涨99.22%，近5个交易日跌0.33%，近20日跌0.75%，近60日涨5.65%。 截至9月30日，昭衍新药股东户数9.65万，较上期增加57.61%；人均流通股0股，较上期增加0.00%。 2025年1月-9月，昭衍新药实现营业收入9.85亿元，同比减少26.23%；归母净利润8070.61万元，同比增 长214.79%。 分红方面，昭衍新药A股上市后累计派现7.03亿元。近三年，累计派现3.56亿元。 机构持仓方面，截止2025年9月30日，昭衍新药十大流通股东中，华宝中证医疗ETF（512170）位居第 五大流通股东，持股1248.38万股，相比上期减少216.93万股。广发小盘成长混合(LOF)A（162703）位 ...

甘李药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：创新药、生物医 药、医疗器械、多肽药、基金重仓等。 截至9月30日，甘李药业股东户数9.47万，较上期增加22.53%；人均流通股5889股，较上期减少 17.81%。2025年1月-9月，甘李药业实现营业收入30.47亿元，同比增长35.73%；归母净利润8.18亿元， 同比增长61.32%。 11月12日，甘李药业盘中上涨2.03%，截至09:50，报65.41元/股，成交1.78亿元，换手率0.49%，总市值 390.70亿元。 资金流向方面，主力资金净流入897.83万元，特大单买入652.78万元，占比3.68%，卖出325.78万元，占 比1.83%；大单买入4254.96万元，占比23.96%，卖出3684.13万元，占比20.75%。 甘李药业今年以来股价涨51.74%，近5个交易日涨1.92%，近20日跌7.73%，近60日涨7.21%。 资料显示，甘李药业股份有限公司位于北京市通州区漷县镇南凤西一路8号，成立日期1998年6月17日， 上市日期2020年6月29日，公司主营业务涉及重组胰岛素类似物原料药及注射剂的研 ...

Core Points - The stock price of Baiotai increased by 2.03% on November 12, reaching 26.59 yuan per share, with a total market capitalization of 11.01 billion yuan [1] - Baiotai's stock has risen by 37.20% year-to-date, but has seen a decline of 1.52% over the past 20 days and 14.25% over the past 60 days [1] Financial Performance - For the period from January to September 2025, Baiotai achieved a revenue of 684 million yuan, representing a year-on-year growth of 17.57% [2] - The net profit attributable to the parent company was -224 million yuan, showing a year-on-year increase of 38.72% [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Baiotai was 9,397, a decrease of 0.89% from the previous period [2] - The average number of circulating shares per shareholder increased by 0.89% to 44,065 shares [2] - Hong Kong Central Clearing Limited is the tenth largest circulating shareholder, holding 6.02 million shares as a new shareholder [2] Company Overview - Baiotai Biopharmaceutical Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on July 28, 2003, with its listing date on February 21, 2020 [1] - The company's main business involves the research, development, and production of innovative drugs and biosimilars, with 91.90% of its revenue coming from drug sales [1]